4.7 Article

Sulforaphane alleviates hyperalgesia and enhances analgesic potency of morphine in rats with cancer-induced bone pain

期刊

EUROPEAN JOURNAL OF PHARMACOLOGY
卷 909, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.ejphar.2021.174412

关键词

Sulforaphane; Nrf2; HO-1; MOR; Cancer-induced bone pain; Spinal cord

资金

  1. National Natural Science Foundation of China [81901124, 82001176]
  2. Natural Science Foundation of Zhejiang Province of China [LY20H090020, LGF20H090021, LQ19H090007]
  3. Medical and Health Science and Technology Research Program of Zhejiang Province [2020RC124, 2020RC122]
  4. Science and Technology Project of Jiaxing City [2020AY30009]
  5. Key Discipline by Zhejiang Province and Jiaxing City Jointly - Pain Medicine [2019-ss-ttyx]
  6. Key Discipline of Anesthesiology of Jiaxing City [2019-zc-06]
  7. Jiaxing Key Laboratory of Neurology and Pain Medicine

向作者/读者索取更多资源

The study showed that SFN can alleviate pain hypersensitivity caused by cancer, activate Nrf2 and HO-1, inhibit NF-kappa B and reduce inflammation-related factors. Additionally, SFN inhibits proliferation of Walker 256 cells, promotes MOR expression in SH-SY5Y cells, and enhances the antihyperalgesic effects of morphine by restoring MOR expression in the spinal cord.
Due to the efficacy and tolerability of the available drugs, the current treatment for cancer-induced bone pain (CIBP) is not considered ideal, and new drugs are required for better treatment results. This study investigated whether intrathecal injection of sulforaphane (SFN) can modulates the noxious behavior associated with CIBP and enhances the analgesic effects of morphine and the possible mechanisms related to these effects were investigated. Walker256 breast cancer cells were injected into the bone marrow cavity of rats to establish the CIBP model. When CIBP rats began to exhibit painful behavior (CIBP 6 days), SFN was injected intrathecally for 7 days. The results showed that SFN alleviated the painful behavioral hypersensitivity caused by cancer, accompanied by nuclear factor, erythroid 2 like 2 (Nrf2), Haem oxygenase 1 (HO-1) activation, nuclear factor kappa B (NF-kappa B) inhibition and inflammation-related factors (tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-beta), interleukin-6 (IL-6), and inducible nitric oxide synthase (iNOS) reduction. In addition, SFN treatment inhibited the proliferation of Walker 256 cells in a dose-dependent manner, promoted mu-opioid receptor (MOR) expression in SH-SY5Y cells and enhanced the antihyperalgesic effects of morphine on CIBP rats by restoring the downregulation of MOR expression in the spinal cord. Interestingly, the antihyperalgesic effects of SFN were partially blocked by opioid receptor antagonists. This study showed that SFN combined with morphine might be a new way to treat CIBP.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据